All Photos(1)
(S)-2-((S)-1-((S)-2-((S)-2-((tert-Butoxycarbonyl)amino)propanamido)-2-cyclohexylacetyl)pyrrolidine-2-carboxamido)-3-(4-fluorophenyl)propanoic acid, IAP E3 ligase lead for protein degrader research, SNIPER building block
C30H43FN4O7
Recommended Products
ligand
BocA1V2PF2
Quality Level
form
powder
reaction suitability
reagent type: ligand
functional group
carboxylic acid
storage temp.
2-8°C
SMILES string
C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=C(C=C2)F)=O)=O)C3CCCCC3)=O
Related Categories
Application
BocA1V2PF2 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlights. A C-terminal variant of BocA1V2PF2 is also available as A1V2PF2-NHEt (916714).
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
Other Notes
Legal Information
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
related product
Product No.
Description
Pricing
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service